Fudan University Shanghai Cancer Center
Shanghai, China
Location status: Recruiting
NCT Number: NCT03786003
This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1007). The goal of this study is to determine video-assisted thoracoscopic surgery is non-inferior to thoracotomy in terms of disease-free survival for solid clinical stage T1N0M0 NSCLC.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Shanghai, China
Location status: Recruiting
It is a randomized clinical trial comparing video-assisted thoracoscopic surgery (VATS) with thoracotomy for solid clinical stage T1N0M0 NSCLC. The primary objective of the study is to determine that VATS is non-inferior to thoracotomy in terms of disease-free survival (DFS). Secondary objectives are to compare VATS and thoracotomy for overall survival (OS), perioperative complications, pain levels and quality of life.
Although there are numerous retrospective studies have indicated feasibility and effectiveness of VATS, no data has been reported from those prospective and randomized clinical trials with prognostic indicators as the primary objective. Whether VATS is non-inferior to thoracotomy in terms of survival is still unclear. Therefore, we design this trial by recruiting patients in clinical stage T1N0M0 with solid mass on computed tomography (CT). To determine the clinical stage, CT scans will be performed routinely and PET-CT/EBUS-TBNA/mediastinoscopy will be conducted in patients with suspected positive mediastinum lymph node or distant metastases. Detailed inclusion criteria include clinical stage T1N0M0 and surgical resectable, solid appearance on CT, age 18 to 75 year and signed informed consent. Exclusion criteria includes not NSCLC in pathologic analysis, no lobectomy or sublobar resection, history of other malignant tumors within 5 years, history of thoracic surgery or unsuitable for VATS and previous radiation or chemotherapy.
In our previous data, the 3-year DFS for cT1N0M0 patients with solid mass who were subjected to thoracotomy (lobectomy or sublobar resection) was 77.9%. If the 3-year DFS of VATS arm is not less than 70.9%, the VATS arm will be regarded to be non-inferior to thoracotomy. A sample size of at least 1086 participants is required for performance equal to 80%, α-level equal to 0.025, 1:1 recruitment and considering a dropout rate of 10%. Participants will be randomly assigned to either group using a random table.
Lobectomy or sublobar resection will be conducted by standard procedures at the discretion of the surgeon. Each participating surgeon will be evaluated by the trial committee to ensure proper surgical technique. If the VATS is diverted to thoracotomy intraoperartively, the reason will be recorded, and the cause will still be analyzed in an intention-to-treat analysis. Patients will be follow-up every 6 months to 3 years after surgery.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard video assisted thoracic surgery, no use of rib-spreader.
Standard thoracotomy
Time frame: 3 years after the surgery
Disease-free survival means the period after surgery when no disease can be detected.
Time frame: 3 years after the surgery
Overall survival means the period after surgery when a patient doesn't die directly from lung cancer or an unrelated cause.
Time frame: 1 month after surgery
The perioperative complication includes wound infection, hemorrhage, infection, pleural effusion, pneumothorax, cardiovascular problem and etc within a month after surgery.
Time frame: 1 years after the surgery
Numerical rating score (NRS)
Contact information is provided by the study sponsor or research team.
Fudan University
Other
Lobectomy for Clincial Stage T1N0M0 Solid NSCLC by VATS Versus Thoracotomy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06623422
Bronchial Neoplasms, Carcinoma, Bronchogenic
Gilbert, Arizona, United States
View Trial DetailsNCT07230691
Bronchial Neoplasms, Carcinoma, Bronchogenic
Graz, Austria
View Trial DetailsNCT07227025
Bronchial Neoplasms, Carcinoma, Bronchogenic
New York, United States
View Trial DetailsNCT06667076
Bronchial Neoplasms, Carcinoma, Bronchogenic
Daphne, Alabama, United States
View Trial Details